Assessment of response of neoadjuvant chemotherapy in carcinoma breast patients by high-frequency ultrasound.
Breast
NACT
carcinoma
ultrasound
Journal
Journal of family medicine and primary care
ISSN: 2249-4863
Titre abrégé: J Family Med Prim Care
Pays: India
ID NLM: 101610082
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
05
11
2021
revised:
08
02
2022
accepted:
10
02
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
11
11
2022
Statut:
ppublish
Résumé
To assess the response of neoadjuvant chemotherapy in carcinoma breast patients by high-frequency ultrasound. The current single blind, observational study was conducted at rural tertiary healthcare center of Acharya Vinoba Bhave Rural Hospital from October 2018 to Sept 2020. We incorporated breast cancer patients with TNM stages IIIA and IIIB who received neoadjuvant chemotherapy with Cyclophosphamide/Adriamycin/5 FU and Paclitaxel respectively followed by standard surgical procedure modified radical mastectomy. Successive ultrasound examination of the breast malignancy and the axilla was done after 21 days of either of any neoadjuvant chemotherapy for 3 cycles. Assessment of response to neoadjuvant chemotherapy was applied in terms of reduction in the breast tumour volume on ultrasound and percentage of tumour response calculated by Response Evaluation Criteria for Solid Tumours (RECIST). Data were analysed using SPSS version 24.0. Higher frequency of patients was invasive ductal breast cancer. In our study, Paclitaxel group showed better response in terms of CR and PR than CAF group. Our study noticed a consistent decrement in tumour volume after every cycle of either CAF or Paclitaxel NACT. Axillary ultrasound was able to predict the response of axillary lymph nodes in terms of increase or decrease in number and morphological changes after 3 cycles of NACT with similarity on final histopathology. It can be concluded from the results of the present study that high-frequency ultrasound is appropriate tool for assessment of response of primary breast malignancy and lymphnode metastasis in the axilla after neoadjuvant chemotherapy.
Identifiants
pubmed: 36353032
doi: 10.4103/jfmpc.jfmpc_2186_21
pii: JFMPC-11-4717
pmc: PMC9638649
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4717-4722Informations de copyright
Copyright: © 2022 Journal of Family Medicine and Primary Care.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Clin Oncol. 2015 Oct 20;33(30):3386-93
pubmed: 25646192
J Family Med Prim Care. 2014 Oct-Dec;3(4):340-4
pubmed: 25657940
Indian J Cancer. 2016 Apr-Jun;53(2):220-225
pubmed: 28071613
Radiology. 1994 Mar;190(3):825-30
pubmed: 8115634
Ann Oncol. 2013 Mar;24(3):655-61
pubmed: 23104719
Int J Biol Sci. 2017 Nov 1;13(11):1387-1397
pubmed: 29209143
Oncol Lett. 2019 Oct;18(4):3873-3879
pubmed: 31516598
Oncotarget. 2017 May 30;8(22):36696-36706
pubmed: 27852041
Am Surg. 2005 Jun;71(6):487-92
pubmed: 16044927
Ann Surg Oncol. 2016 Mar;23(3):789-95
pubmed: 26467456
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancers (Basel). 2021 Jul 14;13(14):
pubmed: 34298733
AJR Am J Roentgenol. 2005 Mar;184(3):868-77
pubmed: 15728611
Ultrasound Med Biol. 2008 Jun;34(6):857-66
pubmed: 18374468
J Breast Health. 2015 Apr 1;11(2):59-66
pubmed: 28331693
World J Surg Oncol. 2007 Aug 28;5:99
pubmed: 17725837
Asia Pac J Clin Oncol. 2017 Aug;13(4):289-295
pubmed: 28181405
Oncol Rep. 2014 Apr;31(4):1555-60
pubmed: 24535214
Indian J Radiol Imaging. 2009 Jul-Sep;19(3):242-7
pubmed: 19881096
Breast. 2018 Jun;39:19-23
pubmed: 29518677